Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide

Inclusion Criteria

• •Male or female subjects aged between 18 and 45 years, inclusive.
• •Subjects of body mass index (BMI) between 19 and 30 kg/m2, inclusive.
• •Subjects who were healthy as determined by pre-study medical history, physical examination, vital signs, complete neurological examination and 12-lead ECG.
• •Subjects who had clinical laboratory test results clinically acceptable at screening and admission to first treatment period.
• •Subjects who had negative tests for HBsAg, anti-HCVAb and HIV-1 and HIV-2 Ab at screening.
• •Subjects who had a negative screen for alcohol and drugs of abuse at screening and admission to each treatment period.
• •Subjects who were non-smokers or who smoked ≤ 10 cigarettes or equivalent per day.
• •Subjects who were able and willing to give written informed consent.
• •(If female) She was not of childbearing potential by reason of surgery or, if of childbearing potential, she used one of the following methods of contraception: double barrier, intrauterine device or abstinence.
• •(If female) She had a negative urine pregnancy test at screening and admission to each treatment period.
• •Subjects who had a clinically relevant history or presence of respiratory, gastrointestinal, renal, hepatic, haematological, lymphatic, neurological, cardiovascular, psychiatric, musculoskeletal, genitourinary, immunological, dermatological, endocrine, connective tissue diseases or disorders.
• •Subjects who had a clinically relevant surgical history.
• •Subjects who had a clinically relevant family history.
• •Subjects who had a history of relevant atopy.
• •Subjects who had a history of relevant drug hypersensitivity.
• •Subjects who had a history of glaucoma.
• •Subjects who had a history of alcoholism or drug abuse.
• •Subjects who consumed more than 21 units of alcohol a week.
• •Subjects who had a significant infection or known inflammatory process on screening or first admission.
• •Subjects who had acute gastrointestinal symptoms at the time of screening or first admission (e.g., nausea, vomiting, diarrhoea, heartburn).
• •Subjects who had used medicines within 2 weeks of first admission that, in the opinion of the investigator, may affect the safety or other study assessments.
• •Subjects who had used any investigational drug or participated in any clinical trial within 2 months of their first admission.
• •Subjects who had donated or received any blood or blood products within the previous 2 months prior to screening.
• •Subjects who were vegetarians, vegans or have medical dietary restrictions.
• •Subjects who could not communicate reliably with the investigator.
• •Subjects who were unlikely to co-operate with the requirements of the study.
• •Subjects who were unwilling or unable to give written informed consent.
• •(If female) She was pregnant or breast-feeding.
• •(If female) She was of childbearing potential and she did not use an approved effective contraceptive method (double-barrier, intra-uterine device or abstinence) or she used oral contraceptives.